Neurocrine Biosciences
NBIX
#1320
Rank
A$25.19 B
Marketcap
A$248.93
Share price
-2.87%
Change (1 day)
10.35%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Earnings for Neurocrine Biosciences (NBIX)

Earnings in 2026 (TTM): A$1.25 Billion

According to Neurocrine Biosciences 's latest financial reports the company's current earnings are A$3.70 Billion. In 2025 the company made an earning of A$1.03 Billion, an increase over its 2024 earnings that were of A$0.90 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Neurocrine Biosciences from 1996 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) A$1.25 B21.67%
2025 A$1.03 B14.74%
2024 A$0.90 B96.41%
2023 A$0.45 B41.13%
2022 A$0.32 B73.74%
2021 A$0.18 B-8.82%
2020 A$0.20 B77.78%
2019 A$0.11 B49.83%
2018 A$76.95 M-142.57%
2017 -A$0.19 Billion-14.73%
2016 -A$0.22 Billion53.15%
2015 -A$0.14 Billion46.25%
2014 -A$94.66 Million29.66%
2013 -A$73.01 Million-3530.8%
2012 A$2.12 M-95.73%
2011 A$49.84 M
2009 -A$70.08 Million-45.38%
2008 -A$0.13 Billion-58.87%
2007 -A$0.32 Billion87.3%
2006 -A$0.17 Billion351.97%
2005 -A$36.85 Million-52.09%
2004 -A$76.91 Million-10.98%
2003 -A$86.39 Million
2001 -A$64.49 Million
1999 -A$29.09 Million108.32%
1998 -A$13.97 Million
1996 A$4.26 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Pfizer
PFE
A$10.23 B 707.42%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
A$18.83 B 1,384.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$51.09 B 3,928.88%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
A$45.08 M-96.45%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-A$61.37 Million-104.84%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
A$0.23 B-81.71%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-A$12.31 Million-100.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
A$2.26 B 78.95%๐Ÿ‡ฌ๐Ÿ‡ง UK